Rivaroxaban in the Real World

    loading  Checking for direct PDF access through Ovid

Abstract

A large Phase IV registry study shows that rivaroxaban is associated with a very low incidence of major bleeding, death, or stroke. Also, adherence to therapy was much higher than observed in other studies with vitamin K antagonists.

Related Topics

    loading  Loading Related Articles